{{Rsnum
|rsid=4712653
|Gene=LINC00340
|Chromosome=6
|position=22125735
|Orientation=plus
|GMAF=0.348
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CASC15
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 16.8 | 51.3 | 31.9
| HCB | 54.4 | 35.3 | 10.3
| JPT | 47.3 | 49.1 | 3.6
| YRI | 78.2 | 21.1 | 0.7
| ASW | 72.7 | 27.3 | 0.0
| CHB | 54.4 | 35.3 | 10.3
| CHD | 62.4 | 30.3 | 7.3
| GIH | 34.0 | 54.0 | 12.0
| LWK | 70.9 | 28.2 | 0.9
| MEX | 50.0 | 39.7 | 10.3
| MKK | 63.2 | 33.5 | 3.2
| TSI | 20.6 | 52.9 | 26.5
| HapMapRevision=28
}}SNPs clustered in one region of chromosome 6p22 have been linked to increased risk for the exceedingly rare childhood cancer known as [[neuroblastoma]]. A study involving 720 patients determined that [[rs4712653]](C;C) genotypes had increased likelihood of [[neuroblastoma]] development (odds ratio 1.96, CI: 1.57 to 2.43, p=7 x 10<sup>-8</sup>). At-risk homozygotes diagnosed with [[neuroblastoma]] had, on average, more malignant clinical presentation, more aggressive disease, and poorer long-term survival.{{PMID|18463370|OA=1
}} 

For more information on this cluster of SNPs, see [[rs6939340]].

{{omim
|id=256700
|desc=NEUROBLASTOMA
|rsnum=4712653
}}

{{PMID Auto GWAS
|PMID=21124317
|Trait=None
|Title=Integrative genomics identifies LMO1 as a neuroblastoma oncogene
|RiskAllele=C
|Pval=8E-17
|OR=1.4000
|ORtxt=[NR]
|OA=1
}}
{{omim
|id=613015
|rsnum=4712653
}}

{{PMID|19412175|OA=1
}} Common variations in BARD1 influence susceptibility to high-risk neuroblastoma.

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}